Eisai Unveils New Findings on the Ongoing and Growing Advantages of LEQEMBI® (lecanemab-irmb) Maintenance Therapy for Early Alzheimer’s Disease at the 2025 Clinical Trials on Alzheimer’s Disease (CTAD) Conference

LEQEMBI Treatment Benefits: Long-term treatment with LEQEMBI may delay the progression of Alzheimer's disease from Mild Cognitive Impairment (MCI) to moderate stages by up to 8.3 years, particularly in patients with low amyloid levels who start treatment early.

Subcutaneous Formulation: New data presented at the CTAD Conference indicates that a subcutaneous formulation of LEQEMBI maintains similar efficacy and safety to intravenous administration, with a low incidence of systemic infusion reactions.

Clinical Trial Findings: Analysis from clinical studies suggests that early initiation of LEQEMBI treatment can significantly slow disease progression, with time savings of up to 6 years in low-amyloid patients compared to untreated groups.

Safety Considerations: LEQEMBI is associated with risks of Amyloid-Related Imaging Abnormalities (ARIA), particularly in ApoE ε4 homozygotes, necessitating careful monitoring and consideration of patient history before treatment initiation.